IMMUNOMEDICS CEA-SCAN DIAGNOSTIC IMAGING AGENT FOR COLORECTAL CANCER TO BE LAUNCHED THIS FALL WITH EDUCATION PROGRAMS FOR NUCLEAR, ONCOLOGY SPECIALISTS
This article was originally published in The Gray Sheet
Executive Summary
Immunomedics CEA-Scan (arcitumomab) diagnostic imaging agent will be launched this autumn for sale to hospitals, Immunomedics said following FDA's June 28 approval of the monoclonal antibody-based agent.